BSEB Teacher Competency Test 2025: Check schedule for Phase 3, 4 and 5 here. (Representative image) Addressing a press conference, BSEB Chairman Anand Kishore announced that the third phase of the ...

Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital ...

It’s been eight months since the Union government approved two corridors under Bengaluru Metro Phase 3 at an estimated cost of Rs 15,611 crore, but Bangalore Metro Rail Corporation Ltd (BMRCL ...

Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Presentation Details: Presenting Author: Andrew T. Kuykendall, M.D. (Moffitt Cancer Center) Title: Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with ...

The phase 3 programme will be conduced across approximately 200 investigation sites, eventually enrolling around 1,800 patients, and should generate results in 2024, according to Grünenthal's ...

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 ...

Bristol Myers Squibb will complete a full evaluation of the Phase 3 trial data and intends to present detailed results at an upcoming medical conference. Bristol Myers Squibb thanks the patients ...

Dr. DeWeese has no relationship with Candel, other than serving as the national principal investigator for Candel’s phase 3 clinical trial of CAN-2409 in patients with intermediate-to-high risk ...

will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology ...